You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The changes follow a strategic review and are part of the company's previously announced plans for growing its revenues and reducing costs.
The company will rely more on distribution partners in Europe for its Unyvero product line while continuing highly targeted commercialization efforts in the US.
Pathology groups throughout the health system are being grouped hub and spoke into networks to better manage staffing needs and control costs.
Cooper took a $24.4 million impairment charge in the second quarter on the intangible assets it acquired in 2016 from carrier screening firm Recombine.
The company entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.
The restructuring and job cuts are expected to save the firm more than $70 million annually.
Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.
The company said that it is extending the maturity of certain obligations under the terms of the acquisition deal until March 2019.
After a 54 percent quarter over quarter rise in sales of the test, Rosetta's CEO said that the realigned strategy will take the firm to profit more quickly.
As part of the deal with an institutional investor, Interpace's royalty and milestone obligations will also be terminated.